The ticker symbol IMRX represents the common stock of Immuneering Corporation, a clinical-stage oncology biotechnology enterprise listed on the NASDAQ exchange. The company utilizes its proprietary computational and experimental platforms to discover and develop novel, dual-mechanism kinase inhibitors designed to treat various forms of cancer driven by RAS and RAF mutations, aiming to improve therapeutic outcomes for oncology patients.